Developing novel therapies for virus-mediated immune disorders
Better targets, Better antibodies, Better patient treatments
100% free to get started!
Our Solution
Immunogenic epitope prediction is difficult:
Current approaches miss clinically relevant targets or prioritise sub-optimal epitopes, resulting in:
High attrition rate in therapeutic development, wasted R&D expenditure, disease areas without effective immunotherapies
Maxitope Platform: structure guided antigen discovery platform
Red Peak Workflow
Rational
Design
Maxitope predicts structurally stable, surface-exposed epitopes.
Biological Validation
Predicted epitopes screened against patient serum to confirm immunogenicity.
Human B-cell mining
Naturally affinity-matured mAbs are isolated from disease-relevant patient B-cells.
Therapeutic mAb product
Fully human leads with reduced immunogenicity risk.
We discover antibodies directly from human B-cell repertoires, eliminating the need for humanisation and ensuring native, physiologically selected binders.
Lead Therapeutic Program
We are developing a first-in-class Monoclonal Antibody for the treatment of Multiple Sclerosis
We discover antibodies directly from human B-cell repertoires, eliminating the need for humanisation and ensuring native, physiologically selected binders.
Proof of Concept: SARS-CoV-2
Maxitope independently validated through:
- Identification of novel antigenic targets
- Identified ‘M1’ a critical non-spike epitope overlooked during pandemic efforts
- Generation of mAbs against target
- Demonstrated clear superiority over existing discovery methods
Platform Scope: Disease-Agnostic
- Initial programs focus on viruses that drive autoimmune diseases
- Maxitope platform can be applied broadly to infectious disease, oncology and beyond
- Maxitope enables rapid epitope discovery across any disease area when antibody therapeutics and vaccines are relevant
IP and
Publications
- Patent protecting core Maxitope platform
- Ongoing filings for novel specific targets
- Publication using Maxitope platform for SARS epitope identification
- Focused target publication in submission
Red Peak Therapeutics Team
The Maxitope platforms was developed by leading experts at the University of Edinburgh. Red Peak Therapeutics is led by a multidisciplinary founding team with deep expertise in immunology, structural biology and commercial translation
Dr Patrick Kearns
Founder
Neurologist, expert in biotherapeutic treatments in a clinical setting.
Prof Nick Gilbert
Founder, CSO
Molecular geneticist and strategic innovation lead.
Prof Joe Marsh
Founder
Expert in structural bioinformatics and protein-protein interactions.
Dr Isabel Dodd
Commercial Lead
Experienced in company creation and investment.
Dr Charles Dixon
Principal Scientist
Technology translation and demonstration. Commercially focused bio scientist.
Contact Us
Get In Touch
